|
Aug 7
|
Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement
|
|
Sep 19
|
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
|
|
Aug 10
|
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
|
|
Aug 7
|
Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer
|